Therapeutic Advances in Neurological Disorders This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction
Conclusions: In seven of the eight patients, SCIG gave improved tolerability and patient satisfaction with similar efficacy compared with IVIG. (Source: Therapeutic Advances in Neurological Disorders)
Source: Therapeutic Advances in Neurological Disorders - January 6, 2015 Category: Neurology Authors: Hadden, R. D. M., Marreno, F. Tags: Original Research Source Type: research

Towards the implementation of 'no evidence of disease activity' in multiple sclerosis treatment: the multiple sclerosis decision model
Conclusion: The MSDM aims to support early treatment decisions and uncover timely treatment failure. Prospective investigations are required to prove that such a disease-monitoring concept leads to an early and effective silencing of disease activity. (Source: Therapeutic Advances in Neurological Disorders)
Source: Therapeutic Advances in Neurological Disorders - January 6, 2015 Category: Neurology Authors: Stangel, M., Penner, I. K., Kallmann, B. A., Lukas, C., Kieseier, B. C. Tags: Original Research Source Type: research

Rituximab postprogressive multifocal leukoencephalopathy: a Feasible therapeutic option in selected cases
(Source: Therapeutic Advances in Neurological Disorders)
Source: Therapeutic Advances in Neurological Disorders - November 2, 2014 Category: Neurology Authors: Hoepner, R., Faissner, S., Ellrichmann, G., Schneider, R., Gold, R. Tags: Letter to the Editor Source Type: research

Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome
The BEtaferon®/BEtaseron® in Newly Emerging MS For Initial Treatment (BENEFIT) trial assessed the efficacy of early versus delayed treatment with interferon beta-1b for patients with clinically isolated syndrome (CIS). Patients were randomly assigned to receive either interferon beta-1b 250 μg every other day (early treatment, n = 292) or placebo (delayed treatment, n = 176) for 2 years or until progression to clinically definite multiple sclerosis. Clinical and magnetic resonance imaging (MRI) outcomes were assessed after 2 years (at the end of the placebo-controlled phase) and then again at 3, 5, and 8 years p...
Source: Therapeutic Advances in Neurological Disorders - November 2, 2014 Category: Neurology Authors: Freedman, M. S. Tags: Review Source Type: research

High noon back pain- severe pseudoradicular pain as a lead symptom of superficial siderosis: a case report
We present a case with the most severe pseudoradicular lumbosacral pain occurring daily at noon for the past 5 weeks. The 48-year-old male white patient did not complain of pain in the morning. A traumatic root avulsion 26 years earlier led to a brachial plexus palsy and Horner’s syndrome in this patient. Superficial hemosiderosis in cranial MRI and examination of the cerebrospinal fluid revealing massive red blood cells as well as xanthochromia and elevated protein levels (742 mg/l) led to the diagnosis of a superficial siderosis. A pseudomeningocele caused by a cervical nerve root avulsion is described as a rare re...
Source: Therapeutic Advances in Neurological Disorders - November 2, 2014 Category: Neurology Authors: Saft, C., Siglienti, I., Gold, R., Schlamann, M., Hindy, N. E., Sure, U., Forsting, M. Tags: Original Research Source Type: research

Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis
Conclusions: Our results suggest that route of administration and treatment frequency play an important role in the patients’ preference for a given DMT. (Source: Therapeutic Advances in Neurological Disorders)
Source: Therapeutic Advances in Neurological Disorders - November 2, 2014 Category: Neurology Authors: Utz, K. S., Hoog, J., Wentrup, A., Berg, S., Lammer, A., Jainsch, B., Waschbisch, A., Lee, D.-H., Linker, R. A., Schenk, T. Tags: Original Research Source Type: research

Isoniazid in autoimmunity: a trigger for multiple sclerosis?
We present the case of a patient with primary progressive multiple sclerosis whose disease commenced weeks after initiating INH therapy for prevention of tuberculosis. Possible mechanisms by which INH may trigger autoimmunity in humans are discussed. (Source: Therapeutic Advances in Neurological Disorders)
Source: Therapeutic Advances in Neurological Disorders - August 19, 2014 Category: Neurology Authors: Nourbakhsh, B., Stuve, O. Tags: Reviews Source Type: research

Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects
A number of novel oral agents are now approved for use in relapsing multiple sclerosis (MS). Among these agents, teriflunomide has shown promise with respect to clinical efficacy and safety in relapsing MS patients. In this review we aim to clarify the role of teriflunomide in the context of current and emerging MS treatment options by summarizing relevant points on the use of teriflunomide in MS, with a discussion of teriflunomide’s pharmacologic properties, pivotal clinical trials, and safety and tolerability. (Source: Therapeutic Advances in Neurological Disorders)
Source: Therapeutic Advances in Neurological Disorders - August 19, 2014 Category: Neurology Authors: Oh, J., O'Connor, P. W. Tags: Reviews Source Type: research

Fumarate treatment in progressive forms of multiple sclerosis: first results of a single-center observational study
Conclusion: Our pilot data indicate that fumarate therapy appears to be safe and well tolerated by patients with progressive MS. In more than 75% of cases no further disease progression was evident. However, controlled studies are warranted to evaluate the detailed therapeutic potential of fumarates and their long-term effects in progressive MS. (Source: Therapeutic Advances in Neurological Disorders)
Source: Therapeutic Advances in Neurological Disorders - August 19, 2014 Category: Neurology Authors: Strassburger-Krogias, K., Ellrichmann, G., Krogias, C., Altmeyer, P., Chan, A., Gold, R. Tags: Original Research Source Type: research

Extended interval dosing of natalizumab: a two-center, 7-year experience
Conclusion: Natalizumab is effective in controlling MS as very few clinical relapses were observed in our dataset. We found that EID did not compromise the treatment effect as measured by relapse rate and no significant breakthrough disease activity was observed. EID is an optional regimen for maintenance natalizumab therapy, but prospective studies are warranted to determine its efficacy. (Source: Therapeutic Advances in Neurological Disorders)
Source: Therapeutic Advances in Neurological Disorders - August 19, 2014 Category: Neurology Authors: Bomprezzi, R., Pawate, S. Tags: Original Research Source Type: research

A review of the use of magnetic resonance imaging in Parkinson's disease
To date, the most frequently used Parkinson’s disease (PD) biomarkers are the brain imaging measures of dopaminergic dysfunction using positron emission tomography and single photon emission computed tomography. However, major advances have occurred in the development of magnetic resonance imaging (MRI) biomarkers for PD in the past decade. Although conventional structural imaging remains normal in PD, advanced techniques have shown changes in the substantia nigra and the cortex. The most well-developed MRI markers in PD include diffusion imaging and iron load using T2/T2* relaxometry techniques. Other quantitative b...
Source: Therapeutic Advances in Neurological Disorders - July 4, 2014 Category: Neurology Authors: Pyatigorskaya, N., Gallea, C., Garcia-Lorenzo, D., Vidailhet, M., Lehericy, S. Tags: Reviews Source Type: research

Defining a role for laquinimod in multiple sclerosis
This article reviews current experimental and clinical evidence on the role of laquinimod in patients with this disabling disease. (Source: Therapeutic Advances in Neurological Disorders)
Source: Therapeutic Advances in Neurological Disorders - July 4, 2014 Category: Neurology Authors: Kieseier, B. C. Tags: Reviews Source Type: research

Para-dichlorobenzene toxicity - a review of potential neurotoxic manifestations
Conclusions: PDCB and other aromatic hydrocarbons are capable of CNS tissue damage and in promoting functional neurological decline. While very little is currently known about prevalence of PDCB addiction, it cannot be ruled out that its illicit use among young people is under-recognized. The number of cases of PDCB toxicity might also rise due to the increasing industrial and domestic use of this chemical. (Source: Therapeutic Advances in Neurological Disorders)
Source: Therapeutic Advances in Neurological Disorders - April 22, 2014 Category: Neurology Authors: Dubey, D., Sharma, V. D., Pass, S. E., Sawhney, A., Stuve, O. Tags: Reviews Source Type: research

Experience in the use of clobazam in the treatment of Lennox-Gastaut syndrome
Clobazam is a 1,5-benzodiazepine used successfully worldwide since the 1970s as an anxiolytic and antiepileptic drug. Since its recent Food and Drug Administration (FDA) approval in the United States in 2011 as adjunctive treatment for Lennox–Gastaut syndrome, it has continued to show sustained efficacy and a better safety and tolerability profile compared with other benzodiazepines. The two randomized, controlled studies that led to the US FDA approval, as well as the follow-up multicenter, open-label study of clobazam, showed ≥50% seizure reduction for more than 50% of Lennox–Gastaut syndrome patients, whi...
Source: Therapeutic Advances in Neurological Disorders - April 22, 2014 Category: Neurology Authors: Purcarin, G., Ng, Y.-T. Tags: Reviews Source Type: research

Sphenopalatine ganglion stimulation for the treatment of cluster headache
In this study the majority of adverse events were related to the implantation procedure, which typically resolved or remained mild in nature at 3 months following the implant procedure. This and other studies highlight the promise of using SPG stimulation to treat the pain-associated cluster headache. SPG stimulation could be a safe and effective option for chronic cluster headache. (Source: Therapeutic Advances in Neurological Disorders)
Source: Therapeutic Advances in Neurological Disorders - April 22, 2014 Category: Neurology Authors: Lainez, M. J. A., Puche, M., Garcia, A., Gascon, F. Tags: Reviews Source Type: research